After the most recent webinar I honestly don't see the needle moving much and holding ground until early next year. Key drivers I see will either be an increase in sales via the SAS be that Restorative or Terry White etc. or that they are ready to go live with the Compound Pharmacy sales into the U.S. The TGA engagement is what it is, an engagement and I see the FDA approval coming before the FDA, which is what they have been broadcasting pretty much up until now. Love to be proven wrong though.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-68
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.020(6.45%) |
Mkt cap ! $32.46M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $199.8K | 680.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 58285 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 3162 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| LTP (ASX) Chart |